Drug
Ustekinumab (UST)
Ustekinumab (UST) is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Recruiting2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Trials by Status
completed133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruiting
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
NCT07444060
recruiting
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT06249555
completed
An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients
NCT07057856
Clinical Trials (3)
Showing 3 of 3 trials
NCT07444060
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
NCT06249555
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT07057856
An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3